Welcome to our dedicated page for C4 Therapeutics SEC filings (Ticker: CCCC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
C4 Therapeutics, Inc. filings document the regulatory record for a clinical-stage biopharmaceutical company focused on targeted protein degradation and oncology drug development. Its 8-K reports cover material agreements, including the Roche research collaboration and license agreement for degrader-antibody conjugates, clinical and regulatory disclosures, operating results, business updates, and capital-structure matters involving common stock sales arrangements.
Proxy and governance filings describe board matters, executive compensation, equity awards, shareholder voting items, and by-law provisions, including forum-selection amendments. The filing record also includes Regulation FD disclosures, clinical presentation exhibits for cemsidomide, and other material-event reports tied to the company’s pipeline, collaborations, and public-company governance.
An affiliate of CCCC filed a notice related to potential sales of its common stock. The filing lists up to 4,139 shares of common stock to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services, with a noted date of 08/14/2026 and NASDAQ as the trading market. It also identifies restricted stock originating from issuer grants dated 02/14/2026 and 02/14/2025. In addition, the document details prior sales by Mark Mossler over the last three months, including 15,000 shares for $61,072.50 on 08/13/2026, 19,519 shares for $76,680.39 on 08/12/2026, and 9,087 shares for $35,484.74 on 05/27/2026.
Clearance Capital Holdings (symbol CCCC) filed to allow the sale of 82,563 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services on the NYSE. The shares, with an aggregate market value of $1,899,926.08, consist of multiple equity awards, including restricted stock and performance shares granted between February 14, 2024 and February 15, 2025.
RA Capital Management and affiliated reporting persons report their beneficial ownership in C4 Therapeutics, Inc. common stock in an amended Schedule 13G. As of June 30, 2026, they beneficially owned 11,383,696 shares of common stock, representing 9.99% of the class, with shared voting and dispositive power and no sole power.
The RA Capital Healthcare Fund directly holds 8,000,000 common shares and multiple series of warrants exercisable for additional shares. These include pre-funded, Class A, and Class B warrants, all subject to Beneficial Ownership Blockers that prevent exercises that would raise beneficial ownership above 9.99% of the outstanding common stock.
Lynx1 Capital Management LP and Weston Nichols report beneficial ownership of 15,423,691 shares of C4 Therapeutics, Inc. common stock, including 8,097,000 shares issuable upon exercise of Class A and Class B warrants. Their stake represents 9.9% of the common stock, based on 110,567,222 shares outstanding as of May 1, 2026 and assuming warrant exercise subject to a 9.99% ownership blocker. Voting and dispositive power over all reported shares is shared, with no sole power reported. The filing notes that a prior Schedule 13G in February 2026 inadvertently excluded the warrants from the beneficial ownership calculation. The Lynx1 Master Fund has the right to receive dividends and sale proceeds from the reported shares.
C4 Therapeutics, Inc. has a significant shareholder group led by Squadron Master Fund LP and related parties reporting beneficial ownership of 7,600,000 shares of common stock. This position consists of 7,200,000 shares plus 400,000 shares underlying currently exercisable long call options held by Squadron Capital Management LLC.
The reported holdings represent approximately 6.9% of C4 Therapeutics’ common stock, based on 110,567,222 shares outstanding as of May 1, 2026, plus the option shares. Voting and dispositive powers over all 7,600,000 shares are reported as shared among Squadron Master Fund LP, Squadron Capital Management LLC, and partners Matthew Sesterhenn and William Blank, who each disclaim beneficial ownership beyond their indirect roles.
Mark Mossler filed to sell 15,000 shares of Common Stock of CCCC through Morgan Stanley Smith Barney LLC Executive Financial Services on or after 08/13/2026, with an aggregate market value of $61,072.50 on NASDAQ. The shares were acquired via a stock option exercise paid in cash. Over the prior three months, Mossler reported additional Common Stock sales of 19,519 shares for $76,680.39 on 08/12/2026 and 9,087 shares for $35,484.74 on 05/27/2026.
A holder of C4 Therapeutics, Inc. (CCCC) common stock filed a Form 144 notice to sell up to 19,519 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services, with an aggregate market value of $76,680.39, in connection with a stock option exercise for cash expected on August 12, 2026. The notice also reports that Mark Mossler previously sold 9,087 shares of common stock on May 27, 2026 for an aggregate market value of $35,484.74.
Morgan Stanley and its affiliates reported updated ownership of C4 Therapeutics, Inc. common stock on Schedule 13G/A (Amendment No. 3). Morgan Stanley reported beneficial ownership of 8,862,002 shares of C4 Therapeutics common stock, representing 8.0% of the outstanding class.
Morgan Stanley Capital Services LLC reported beneficial ownership of 8,718,000 shares, or 7.9%, all with shared voting and dispositive power. Morgan Stanley & Co. LLC reported 134,047 shares, or 0.1%, and stated that it has ceased to be the beneficial owner of more than five percent of this class of securities.
C4 Therapeutics reported unaudited results for the quarter ended June 30, 2026, remaining a clinical-stage company with no product sales and revenues derived from collaborations. Revenue from collaboration agreements was $6.6 million in the quarter and $12.8 million for the first half of 2026.
The company recorded a quarterly net loss of $23.6 million and a six‑month net loss of $48.8 million, with operating expenses driven mainly by research and development of its degrader pipeline, including lead program cemsidomide for multiple myeloma and CFT8919 for EGFR‑mutant lung cancer.
Liquidity remains strong, with $300.4 million in cash, cash equivalents, and marketable securities and total assets of $359.4 million as of June 30, 2026. Management states this resource base is expected to fund operations for at least twelve months. A new Roche degrader‑antibody conjugate collaboration added a $20.0 million upfront payment and significant potential milestones and royalties, supplementing existing partnerships with MKDG, Betta Pharma, Roche, Biogen, and Pfizer.
C4 Therapeutics, Inc. reported second quarter 2026 results and provided clinical and corporate updates centered on its IKZF1/3 degrader cemsidomide. For the quarter ended June 30, 2026, revenue from collaboration agreements was $6.6 million, while research and development expense was $24.5 million and general and administrative expense was $8.6 million. Net loss was $23.6 million, or $0.18 per share.
Cash, cash equivalents and marketable securities totaled $300.4 million as of June 30, 2026, supported by a $20 million upfront payment from a new collaboration with Roche and $33.5 million in net proceeds raised through an at-the-market program. The company expects this cash to fund operations through the end of 2028.
Clinically, a Phase 2 multiple myeloma trial of cemsidomide plus dexamethasone is ongoing, with enrollment expected to complete in early 2027 and initial overall response rate data in the second half of 2027. A Phase 1b trial in combination with elranatamab is progressing, and another Phase 1b trial with standard-of-care multiple myeloma therapies is planned to initiate in the first half of 2027.